MX342064B - Novedoso compuesto de imidazo-oxazina o sal del mismo. - Google Patents

Novedoso compuesto de imidazo-oxazina o sal del mismo.

Info

Publication number
MX342064B
MX342064B MX2013011429A MX2013011429A MX342064B MX 342064 B MX342064 B MX 342064B MX 2013011429 A MX2013011429 A MX 2013011429A MX 2013011429 A MX2013011429 A MX 2013011429A MX 342064 B MX342064 B MX 342064B
Authority
MX
Mexico
Prior art keywords
optionally substituted
group
atom
salt
oxazine compound
Prior art date
Application number
MX2013011429A
Other languages
English (en)
Other versions
MX2013011429A (es
Inventor
Mitsuru Ohkubo
Toshiyasu Shimomura
Kenji Niiyama
Masayuki Nakamura
Kaori Kamijo
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2013011429A publication Critical patent/MX2013011429A/es
Publication of MX342064B publication Critical patent/MX342064B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de imidazooxazina representado por la Fórmula (I) o una sal del mismo, (Ver Formula) en donde A, B, C, y D son como se definieron en la especificación.
MX2013011429A 2011-04-06 2012-04-05 Novedoso compuesto de imidazo-oxazina o sal del mismo. MX342064B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011084880 2011-04-06
PCT/JP2012/059376 WO2012137870A1 (ja) 2011-04-06 2012-04-05 新規イミダゾオキサジン化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2013011429A MX2013011429A (es) 2013-12-09
MX342064B true MX342064B (es) 2016-09-12

Family

ID=46969260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011429A MX342064B (es) 2011-04-06 2012-04-05 Novedoso compuesto de imidazo-oxazina o sal del mismo.

Country Status (19)

Country Link
US (1) US8772283B2 (es)
EP (1) EP2698372B1 (es)
JP (1) JP5599941B2 (es)
KR (1) KR101658274B1 (es)
CN (1) CN103459400B (es)
AU (1) AU2012239157B2 (es)
BR (1) BR112013025732B1 (es)
CA (1) CA2830367C (es)
DK (1) DK2698372T3 (es)
ES (1) ES2567605T3 (es)
HK (1) HK1188451A1 (es)
HU (1) HUE027509T2 (es)
MX (1) MX342064B (es)
MY (1) MY163187A (es)
PL (1) PL2698372T3 (es)
RU (1) RU2578608C2 (es)
SG (1) SG193327A1 (es)
TW (1) TWI525097B (es)
WO (1) WO2012137870A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5855250B2 (ja) * 2012-07-02 2016-02-09 大鵬薬品工業株式会社 イミダゾオキサジン化合物による抗腫瘍効果増強剤
US20140275504A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Process for the preparation of certain triaryl rhamnose carbamates
DK3012327T3 (da) * 2013-06-20 2021-01-25 Taiho Pharmaceutical Co Ltd Fremgangsmåde til forudsigelse af terapeutisk effektivitet for pi3k/akt/mtor-hæmmer på basis af phlda1- eller pik3c2b-ekspression
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
DK3023100T3 (da) 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
WO2016136928A1 (ja) * 2015-02-27 2016-09-01 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
EP3279202B1 (en) 2015-03-31 2020-06-24 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
JP7085985B2 (ja) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN111867594A (zh) 2018-03-19 2020-10-30 大鹏药品工业株式会社 包含烷基硫酸钠的药物组合物
WO2020078865A1 (en) 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Use of akt inhibitors in ophthalmology
EP3988175A4 (en) 2019-06-21 2023-06-28 Taiho Pharmaceutical Co., Ltd. Method for treating malignant tumor
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CA3158793A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
US20230023023A1 (en) 2019-10-31 2023-01-26 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US20230255972A1 (en) 2020-07-15 2023-08-17 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
EP4347041A1 (en) 2021-05-28 2024-04-10 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
US11970475B1 (en) 2023-09-05 2024-04-30 King Faisal University 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol as an antimicrobial compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57212188A (en) * 1981-06-25 1982-12-27 Sankyo Co Ltd Imidazobenzoxazine derivative and its preparation
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
DE602005026509D1 (de) * 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
PA8793301A1 (es) * 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados
US9451809B2 (en) 2008-05-29 2016-09-27 Nike, Inc. Article of footwear with a marking system
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CA2750051A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2406250B1 (en) 2009-03-11 2015-08-12 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN103097384B (zh) * 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶

Also Published As

Publication number Publication date
HK1188451A1 (zh) 2014-05-02
KR20140039186A (ko) 2014-04-01
AU2012239157A1 (en) 2013-09-26
RU2013149174A (ru) 2015-05-20
AU2012239157B2 (en) 2015-11-05
TWI525097B (zh) 2016-03-11
EP2698372A4 (en) 2014-09-10
PL2698372T3 (pl) 2016-07-29
WO2012137870A1 (ja) 2012-10-11
MX2013011429A (es) 2013-12-09
BR112013025732A2 (pt) 2016-12-13
KR101658274B1 (ko) 2016-09-22
DK2698372T3 (en) 2016-03-21
ES2567605T3 (es) 2016-04-25
EP2698372B1 (en) 2016-02-03
CA2830367C (en) 2016-08-30
BR112013025732B1 (pt) 2022-02-22
SG193327A1 (en) 2013-10-30
CA2830367A1 (en) 2012-10-11
RU2578608C2 (ru) 2016-03-27
JPWO2012137870A1 (ja) 2014-07-28
CN103459400B (zh) 2016-05-18
TW201247679A (en) 2012-12-01
JP5599941B2 (ja) 2014-10-01
EP2698372A1 (en) 2014-02-19
CN103459400A (zh) 2013-12-18
HUE027509T2 (en) 2016-10-28
MY163187A (en) 2017-08-15
US20140005185A1 (en) 2014-01-02
US8772283B2 (en) 2014-07-08

Similar Documents

Publication Publication Date Title
MX2013011429A (es) Novedoso compuesto de imidazo-oxazina o sal del mismo.
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MX2014000452A (es) Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk).
WO2011141110A3 (de) Photostabilisatoren
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
PH12015500119B1 (en) Composition for controlling plant disease and application therefor
EA201390884A1 (ru) Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса
MX2013001201A (es) Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
MX2014002624A (es) Nuevos derivados biciclicos de dihidroquinolina-2-ona.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MY169267A (en) New aryl-quinoline derivatives
MX343225B (es) Nuevos derivados de aril-benzocicloalquil-amida.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
JO3318B1 (ar) مثبطات bace
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
DK2868660T3 (da) Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse
MX364207B (es) Inhibidores de agrecanasa.
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
MX343077B (es) Nuevo derivado de octahidrotienoquinolina, composicion farmaceutica que comprende el derivado, y uso de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration